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Abstract 
 
In recent years, cost-effectiveness data have strongly influenced clinical practice 
guidelines for several cardiovascular treatments. Economic considerations are increasingly 
common as health systems are under mounting pressure to maximise value for money. The 
quality-adjusted life year (QALY) – an outcome measure that expresses both the duration and 
quality of life – is the main pillar of cost-effectiveness analyses. It is widely used in 
assessments of the clinical and economic value of new cardiovascular treatments, but how the 
QALY is derived is often unclear to clinicians. In this article, we first explain how QALYs 
are defined and calculated. We then review a selected set of cost-effectiveness analyses of 
recently-introduced cardiovascular treatments and outline how these studies derived their 
QALYs. Finally, we discuss the limitations of the QALY and how the presentation of the 
measure could be improved in cost-effectiveness studies. 
 
  
4 
  
Introduction 
 
In many health systems, clinical effectiveness evidence is no longer enough on its 
own to inform coverage, reimbursement, and treatment decisions for new health technologies. 
In recent years, cost-effectiveness data have strongly influenced clinical practice guidelines 
for several cardiovascular treatments, including statins,
1
 drug-eluting stents,
2
 and, more 
recently, novel oral anticoagulants.
3
 Economic considerations are increasingly common as 
health systems are under mounting pressure to maximise value for money.
4, 5
 The quality-
adjusted life year (QALY) – an outcome measure that combines both the duration and quality 
of life – is the main pillar of cost-effectiveness analysis.6 When coupled with cost data, 
QALYs allow decision makers to compare the cost-effectiveness of competing medical 
options. 
Given its high relevance to the practice of cardiovascular medicine, it is important that 
cardiologists are familiar with the information and assumptions that underlie a QALY. In this 
article, we first describe what a QALY is and how it is calculated. To illustrate this further, 
we examine how recent cost-effectiveness analyses of cardiovascular treatments – both drugs 
and medical devices – derived their QALYs. Finally, we discuss the limitations of the QALY 
and how the measure can be improved. 
 
What is a QALY? 
 
Economic evaluations can guide the allocation of scarce health-care resources.  
Researchers usually compare the differences in costs and health benefits of two treatments for 
the same condition in cost-effectiveness analysis. If these studies use clinical endpoints – for 
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example, to calculate the cost per heart attack prevented for two blood-thinning drugs – it is 
not possible to compare the results across health conditions. 
To compare the cost-effectiveness of various treatments, it is necessary to place all 
health outcomes on a single scale. To do this, health economists have developed the QALY, a 
metric that combines the quantity and quality of life. The QALY is a measure of survival 
time adjusted by the quality of that life, which can change over time. The QALY is measured 
on a scale of 0 to 1, where 0 and 1 correspond to the worst and best possible health outcomes, 
respectively; most health conditions lie somewhere in between, although it is possible for the 
lower bound to have a negative value. The 0 to 1 spectrum is an interval scale: an 
improvement in quality of life from 0.1 to 0.2 is considered as equally valuable as a gain 
from 0.9 to 1.0.
7
 
The QALY is widely used to describe the quantity and quality of life of the average 
patient with a particular condition. For example, a recent study reported that the health-
related quality of life of a patient with monthly angina is 0.76, implying that 1 year of life 
with monthly angina is equivalent, quality-wise, to 0.76 years in perfect health.
8
 Cost-
effectiveness studies that use utility as the measure of health benefit (e.g., QALYs) are called 
cost-utility studies, although most researchers use the two terms interchangeably. 
 
Calculating QALYs 
 
Health economists estimate QALYs in several ways. The most common method 
consists of three steps (Figure 1): (1) obtain national preferences about different aspects of 
health; (2) match these preferences to specific conditions to obtain quality-of-life weights – 
also called utilities; and (3) estimate the time spent in a condition to calculate QALYs. 
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[Figure 1 around here] 
 
In the first step, researchers usually ask a random sample of the general public how 
willing they would be to give up years of life with various disabilities to return to perfect 
health.
9
 This is typically done in individual countries to account for international differences 
in people’s preferences. In these surveys, health states are presented to the respondents, often 
using the EuroQol five-dimension (EQ-5D) questionnaire, shown in Figure 2. The EQ-5D 
includes five general aspects of physical, mental, and social well-being, each measured on a 
three-point scale; this corresponds to 243 possible health states. Once a respondent has 
answered the time trade-off question (Figure 2) for numerous hypothetical health states, it is 
possible to estimate the quality-of-life preferences for all 243. Researchers collect these 
answers from large groups of individuals to form nationally-representative preferences about 
the reduction in quality of life associated with various disabilities (see Drummond et al
10
 for a 
review of alternatives to the time-trade off question, some of which are more commonly used 
outside of Europe). 
 
[Figure 2 around here] 
 
The EQ-5D is a generic questionnaire that can be used to describe the quality of life 
of any patient. It is the most common questionnaire in Europe, where it is considered easy to 
administer and sufficiently detailed. Thus far, EQ-5D surveys have been conducted in 13 
countries on randomly-selected samples of between 300 and 4,048 individuals; a Europe-
wide survey was also conducted on 8,709 individuals.
11
 
Second, to estimate the quality-of-life weight associated with specific diseases and 
health conditions, participants in clinical studies are asked to complete the EQ-5D. Their 
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responses are then matched to the respective nationally-representative preferences. For 
example, if a heart-attack survivor in a UK-based clinical study provides an EQ-5D response 
of 2 for mobility, 2 for self-care, 1 for usual activities, 1 for pain/discomfort, and 2 for 
anxiety/depression, these responses would correspond to a quality weight of 0.675 using the 
official UK figures.
12
 The average value from a clinical study can be used to represent the 
quality of life of the average patient with a particular condition. 
In the third step, researchers multiply the quality-of-life weight for a specific 
condition by the length of time spent in that health state. For example, if a heart-attack 
survivor lives, on average, 10 years with a constant quality of life of 0.675, this corresponds 
to 6.75 undiscounted QALYs (10*0.675). In practice, the quality of life associated with an 
intervention often varies over time. Most studies also discount QALYs by around 3.0% per 
year – as conventionally done in economic analyses – under the assumption that people 
generally prefer immediate health benefits over future gains. 
In cost-effectiveness analyses, researchers estimate the difference in QALYs between 
two interventions over the study time period. In the hypothetical example shown in Figure 3, 
patients with heart failure receiving treatment A accrue, on average, 2.15 QALYs over 4 
years, whereas those treated with treatment B accrue 1.25 QALYs. In this scenario, treatment 
A is associated with an increase of 0.9 QALYs over 4 years compared with treatment B. 
 
[Figure 3 around here] 
 
Modelling health outcomes 
 
As described above, cost-effectiveness analyses compare the health outcomes of a 
treatment to those of an alternative, which may be the best, cheapest, or most common 
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treatment (or no treatment). When modelling health outcomes, researchers choose which 
health states to include in their analysis. The key assumption is that the treatment alternatives 
only influence the health states considered in the cost-effectiveness model, and that there are 
no other significant differences in health outcomes between the two treatment arms. This 
ensures that cost-effectiveness analyses are parsimonious and incorporate as few health states 
as possible, instead of the full spectrum of health conditions. 
To model the natural history of a condition, cost-effectiveness studies incorporate data 
on the probability of a patient moving from one health state to another. For example, a model 
will include the probability of a patient experiencing a given event – for example, dying or 
having a stroke – as informed by randomised trials and epidemiological studies. 
The main result of a cost-effectiveness study is the incremental cost-effectiveness 
ratio: the difference in costs between the two competing interventions divided by the 
difference in outcomes – measured in QALYs. The incremental cost-effectiveness ratio is 
presented as the cost per QALY gained. It is outside the scope of this article to review the 
methods for estimating the costs associated with alternative interventions, such as clinician 
visits, procedures and tests, hospitalisations, and medicines; interested readers may wish to 
consult Drummond et al
10
 for a review of costing approaches. 
 
QALYs in cost-effectiveness analyses 
 
To illustrate how QALYs are used in practice, we reviewed four recent cost-
effectiveness analyses (Table 1). These studies were selected to cover a variety of 
interventions (i.e., both drugs and medical devices) and countries. The four studies evaluated 
the cost-effectiveness of: (1) dabigatran versus warfarin for patients with atrial fibrillation;
13
 
(2) cardiac resynchronisation therapy versus optimal medical therapy for patients with 
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asymptomatic to mild heart failure;
14
 (3) ticagrelor versus generic clopidogrel for patients 
with acute coronary syndrome;
15
 and (4) catheter-based renal sympathetic denervation versus 
best medical therapy for patients with resistant hypertension.
16
 The second and third studies 
were conducted as part of the REVERSE (Resynchronization Reverses Remodeling in 
Systolic Left Ventricular Dysfunction)
14
 and PLATO (Platelet Inhibition and Patient 
Outcomes) trials,
15
 respectively. The other two studies obtained many of the clinical inputs 
from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy)
13
 and 
SYMPLICITY
16
 trials. 
 
[Table 1 around here] 
 
The studies included the quality-of-life weights of the key health states that patients 
may experience during the course of their disease (Table 1), such as atrial fibrillation, heart 
attack and failure, hypertension, and stroke. The weights were sometimes listed as 
decrements to health – also called disutilities – which represent the reduction in quality of life 
when a health event occurs (e.g., heart attack) or treatment is initiated (e.g., renal sympathetic 
denervation). All studies discounted the QALYs by either 3.0% or 3.5% per year. 
Here we decompose – using the steps detailed in Figure 1 – the data presented in 
these articles to outline how the researchers arrived at QALYs. 
 
Nationally-representative preferences (step 1): 
 
The four studies were conducted in various countries – Germany, Sweden, and the 
UK. Only two of the studies, however, explicitly stated which national quality-of-life 
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preferences were used.
13, 15
 None of the studies noted which technique was used to elicit the 
national weights (e.g. time trade-off). 
 
Quality-of-life weights (step 2): 
 
The relevant details about the quality-of-life weights were not always reported. Some 
of the studies did not state which patients were asked to complete quality-of-life 
questionnaires and which questionnaires were used (e.g. EQ-5D) (Table 2). 
Two studies obtained the quality-of-life weights from clinical-trial participants.
 
In the 
first,
16 
EQ-5D responses from 18,624 PLATO trial participants were collected at trial onset, 6 
months, and 12 months. The authors of the second study
14
 obtained responses to the 
Minnesota Living With Heart Failure questionnaire – a disease-specific questionnaire – from 
REVERSE participants; these responses were converted to the equivalent EQ-5D responses 
using a published formula. When necessary, the authors of both studies complemented these 
responses with published quality-of-life weights. 
In the other two studies
18,
 
16
 – which were not conducted alongside clinical trials – the 
researchers did not collect any responses to quality-of-life questionnaires and instead relied 
entirely on published quality-of-life weights. 
  
QALYs (step 3): 
 
To extrapolate long-term outcomes and the duration spent in various health states, the 
studies relied primarily on the clinical pathways observed in trials, including PLATO (12 
months),
15
 REVERSE (24 months),
14
 RE-LY (24 months),
13
 SYMPLICITY HTN-1 (24 
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months),
16
 and SYMPLICITY HTN-2 (6 months).
16
 The modelling assumptions were tested 
in sensitivity analyses. 
 
[Table 2 around here] 
 
Overall, there was considerable heterogeneity in the description of the quality-of-life 
data in the models. While some of the studies reported most of the pertinent details about the 
data, others included minimal description of how QALYs were derived (Table 2). Notably, 
none of the studies listed the technique that was used in the first step to estimate the quality-
of-life weights (e.g. time trade-off), and only two of the studies noted which national weights 
were used.  
 
The limitations of QALYs 
 
Although QALYs appeal to health economists, several criticisms are raised against 
the use of QALYs to inform treatment decisions. 
First, many health-care practitioners question the face validity of QALYs. All 
methods used to derive quality-of-life weights make assumptions that are often violated.
7, 17, 
18
 For example, the question presented in Figure 2 is only reliable if the respondent provides 
the same answer regardless of number of years of life in ill health. In other words, it assumes 
that if a respondent is willing to give up two of ten years to return to perfect health, they 
would be willing to give up four of twenty years. If a person provides two different answers – 
which is often the case – it is not possible to elicit the true preference.19 There is empirical 
evidence that most people do not trade duration of life for quality of life in a linear fashion.
20
 
For example, many individuals do not agree that six months in good health is equivalent to 
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one year with quality of life reduced by 50%. More generally, individuals must be very well-
informed about their preferences to answer time trade-off questions accurately. It is a 
challenging conceptual exercise to determine one’s exchange rate between disability and full 
health. In short, the idealized notion of utility put forth by economists is difficult to measure 
in real life. 
Second, the aim to maximise the number of QALYs gained from health spending 
raises equity concerns.
21-23
 All QALYs are of equal value, regardless of who gains or loses 
them, hence the expression that “a QALY is a QALY is a QALY.” However, this is not 
always aligned with societal preferences about the distribution of resources. For example, 
societies may prefer to first help the most vulnerable and unhealthy members, before 
improving the health of those who are already relatively healthy.
7, 24
 QALYs may also 
discriminate against some groups, such as the elderly, for whom interventions may not be as 
cost-effective. As treating younger patients is expected to confer a greater number of QALYs, 
all else equal, QALY maximisation has been labelled by some as “ageist.”25 The debate about 
QALYs is fraught with philosophical and ethical dilemmas. 
Third, for decision makers to act on information from cost-effectiveness studies, it is 
often necessary to define a threshold monetary value that a society is willing to pay for a 
given health improvement, such as an additional QALY gained from an intervention. In 
practice, it is difficult to establish a valid threshold, and there is no consensus on which 
method is most appropriate. The implicit thresholds used in the UK (£20,000-30,000 per 
QALY gained),
26, 27
 the USA ($50,000 per QALY gained),
28
 and other countries are the 
subjects of much debate. 
Fourth, the ability to return to work or to care for family members might be equally 
important to an improvement in health for some people.
29
 QALYs, which focus on absolute 
levels of health, do not capture such benefits. 
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Fifth, generic quality-of-life questionnaires do not cover all dimensions of health 
benefit. For example, as previously described, the EQ-5D (Figure 2) focuses on five general 
aspects of health. Disease-specific questionnaires have also been developed to emphasise the 
aspects of quality of life that are most relevant to patients suffering from particular 
conditions. Notable examples in cardiology include the Seattle Angina
30
 and Kansas City 
Cardiomyopathy
31
 questionnaires. The responses to disease-specific questionnaires are then 
converted to the equivalent response on the EQ-5D or another questionnaire for which 
nationally-representative preferences are available. 
Finally, there is disagreement over which members of the general population should 
be asked to complete the questionnaire described in Figure 2 to generate national quality-of-
life preferences.
32
 Most studies rely on responses from a random sample of the general 
public, as described in this article, to generate societal preferences. Some researchers ask 
patients instead. Patients may overstate the quality of life with their conditions, however, if 
they adapt to life with an illness or disability; conversely, it is possible that the general public 
understates the quality of life with various conditions. Others suggest that researchers should 
ask clinicians given their medical expertise and daily interaction with patients. 
 
The need for standardised reporting 
 
As shown in the reviewed cost-effectiveness studies, the way that QALYs are 
reported and used in cost-effectiveness studies is often non-transparent and difficult to 
scrutinise. The lack of transparency and standardisation in reporting fuels the scepticism 
around QALYs. It is essential for authors to include key information to allow readers to 
accurately interpret the results (Table 2). 
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Nearly two decades ago, the Panel on Cost-Effectiveness in Health and Medicine, an 
expert panel convened by the US Public Health Service, published recommendations for 
reporting cost-effectiveness analyses.
33, 34
 The Panel recommended that studies include a 
"complete description of estimates of quality-of-life weights."
33
 This includes all relevant 
information on how the weights are derived, such as the population that completes the 
qualify-of-life questionnaire and the questionnaire that is used. A second panel has been 
convened to update the earlier recommendations. 
Researchers should strive to adhere to these guidelines, especially as cost-
effectiveness evidence continues to grow in prominence. Figure 1 outlines the key 
components for reporting standardised information on how QALYs are derived. If there are 
space constraints in a journal, these details can be published in online appendixes.  
 
Conclusions 
 
Cost-effectiveness studies influence the coverage, reimbursement, and use of many 
cardiovascular health technologies. QALYs are a widely-used metric in these studies that 
capture both the morbidity and mortality gains of an intervention. The metric allows payers to 
choose between treatments based on how much they prolong the lives and improve the health 
of patients. 
Despite the limitations of QALYs, cost-effectiveness studies that incorporate QALYs 
provide a useful indication of whether new medical interventions provide good value for 
money. Alongside other information, such studies can help inform decisions about whether to 
adopt new treatments. There is a need to educate cardiologists and the wider medical 
community about how QALYs are used in cost-effectiveness analyses to bridge the divide 
between the clinical and health-economic communities. As illustrated by the studies reviewed 
15 
  
in this article, the sources of QALYs are not always clearly outlined in such analyses. To 
enable fruitful dialogue about the strengths and limitations of QALYs, it is important that 
studies report all relevant information in a standardised way. 
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Figure 1. The sequential steps for estimating quality-adjusted life years (QALYs). 
 
Figure 2. Example of how to derive quality of life information on health states. 
 
 
 
 
Mobility 
 
Self-care 
Usual 
activities 
Pain/ 
discomfort 
Anxiety/ 
depression 
Health State 
X 
2 1 2 2 1 
Note: 1 = Best; 3 = Worst 
 
Imagine that you will live 10 years in Health State X (quality of life is described above). 
How many years of life would you be willing to sacrifice to return to perfect health? 
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Figure 3. Example of average quality-adjusted life years (QALYs) gained from hypothetical 
treatment (A versus B). 
 
Note: The QALYs accrued with treatment A versus treatment B for the average patient is shown as the 
highlighted area between the two lines. The figure above only depicts one possible health scenario. As the figure 
is drawn, treatment A leads to a gradual increase from 0.5 to 0.7 in the average patient's quality-of-life weight 
during the 2
nd
 year, whereas an alternative representation might be an immediate improvement from 0.5 to 0.7 
when treatment begins. Similarly, the figure shows a gradual decline in the quality-of-life weights during the 
last year for both treatments, whereas a more abrupt decrease might occur. In other cases, one intervention may 
be associated with longer survival, but no difference in the quality of life. It is also worth noting that time was 
measured in years in the scenario above, but other studies may use other units (e.g., days or weeks). 
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Table 1. Summary of QALY data from selected cost-effectiveness studies in the European Heart Journal. 
Study description Quality-of-life weight* Data source 
Time 
horizon 
National 
preferences 
Cardiac 
resynchronisation 
therapy in patients with 
asymptomatic to mild 
heart failure vs. standard 
medical therapy
14
 
Class I (mild) heart failure:  
0.93 
(1) Another study which used the EQ-5D 
 
(2) Clinical trial (REVERSE-EU) which 
used the Minnesota Living With Heart 
Failure questionnaire; the responses were 
converted to the EQ-5D 
 
10 years Not stated 
Class II (mild) heart failure: 
0.78 
Class III (moderate) heart failure:  
0.61 
Dabigatran in patients 
with atrial fibrillation vs. 
warfarin
13
 
Atrial fibrillation: 
0.81(65-69 year-old patients) 
0.78 (70-74 year-old patients) 
0.76 (75-79 year-old patients) 
0.71 (80-84 year old patients) 
 
0.05 (decrement to quality of life for each 
additional year with atrial fibrillation) (1) Other studies which used the EQ-5D 20 years Sweden 
Ischemic stroke (decrement to quality of life 
at the time of event): 0.15 
Hemorrhagic stroke (decrement to quality of 
life at the time of event): 0.30 
Myocardial infarction (decrement to quality 
of life at the time of event): 0.19 
Catheter-based renal 
sympathetic denervation 
Hypertension: 
0.98 (0.97-0.99) 
(1) Other studies; questionnaire not stated 
 
70 years Not stated 
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in patients with resistant 
hypertension vs. best 
medical therapy
16
 
Myocardial infarction and angina: 
0.88  – first year 
0.90 – subsequent years 
(2) The disutility of percutaneous 
coronary interventions (obtained from 
another study) was used as a proxy for the 
disutility of renal sympathetic denervation 
Stroke: 
0.88 – no sequelae 
0.71 – moderate sequelae 
0.31 – severe sequelae 
Heart failure: 
0.69 
End-stage renal disease: 
0.70 
Disutility of renal sympathetic denervation 
procedure: 
0.06 (decrement to quality of life during each 
year of treatment) 
Ticagrelor in patients 
with acute coronary 
syndrome vs. generic 
clopidogrel
15
 
Non-fatal myocardial infarction: 
0.87 (<69 year-old patients) 
0.84 (70-79 year-old patients) 
0.78 (>80 year-old patients) 
 
0.06 (decrement to quality of life at the time 
of event) 
(1) Clinical trial (PLATO) which used the 
EQ-5D 
 
(2) Another study; questionnaire not stated 
Lifetime 
United 
Kingdom 
Non-fatal stroke: 
0.14 (decrement to quality of life at the time 
of event) 
EQ-5D, EuroQuol five-dimension questionnaire; PLATO, Platelet Inhibition and Patient Outcomes; QALY, quality-adjusted life year; REVERSE, Resynchronization 
Reverses Remodeling in Systolic Left Ventricular Dysfunction 
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* All studies modelled the risk of death at each point in time, with a corresponding quality-of-life weight of 0. 
 
Table 2. Information included in each study about the quality-of-life weights. 
 
 
Step 1 Step 2 Step 3 
Questionnaire Country 
Technique (e.g. 
time trade-off) 
Questionnaire 
Respondents 
(e.g. clinical-
trial patients) 
Duration 
(i.e. observed or 
modelled) 
Cardiac resynchronisation therapy 
in patients with asymptomatic to 
mild heart failure vs. standard 
medical therapy
14
 
 
 
 ✓ ✓ ✓ 
Dabigatran in patients with atrial 
fibrillation vs. warfarin
13
 
✓ ✓  ✓ 
 
✓ 
Catheter-based renal sympathetic 
denervation in patients with 
resistant hypertension vs. best 
medical therapy
16
 
 
 
 
  
✓ 
Ticagrelor in patients with acute 
coronary syndrome vs. generic 
clopidogrel
15
 
✓ ✓  ✓ ✓ ✓ 
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